Insights - Earlier this week, Affimed announced a collaboration with Korean company NKMax to investigate the combination of AFM24, an EGFR engager, with autologous NK cell product … Continue Reading
PremiumResearch - Concert Pharma (CNCE) is developing a deuterated d-serine as an add-on therapy to existing schizophrenia treatments. In historical academic papers, d-serine has shown to enhance the NMDA … Continue Reading
PremiumResearch - The $45M financing last August has given Essa enough funding (~$80M cash) to now pursue combination trials with standard of care anti-androgen drugs used in … Continue Reading
Read nowInsights - Aerpio (ARPO) is developing a novel treatment for glaucoma that has Phase 2 data by the end of 2020. The company’s drug, razuprotafib, has shown to … Continue Reading
PremiumInsights - Affimed (AFMD) announced Q2 results today, which showed that the pipeline is progressing as planned. Below is an update for each candidate: AFM13: On Track … Continue Reading
Read nowInsights - Essa (EPIX) announced an offering after market today. Although details on amount and pricing have not yet been disclosed, we think there will be strong … Continue Reading
PremiumInsights - Fennec announced that the US Patent & Trademark Office will issue U.S. Patent 10,596,190 to Pedmark. The patent is titled “Method for Reducing Ototoxicity in Pediatric Patients … Continue Reading
Read now
